Department of Emergency Medicine, Albany Medical Center, Albany, NY, USA.
Department of Emergency Medicine, MetroHealth Medical Center, Cleveland, OH, USA.
J Vasc Access. 2022 Sep;23(5):788-790. doi: 10.1177/11297298211012212. Epub 2021 Apr 30.
Ultrasound-guided peripheral intravenous (USPIV) catheters are being placed in emergency department (ED) patients with increasing frequency. USPIV catheters have been shown to improve the success rates of cannulation. It is unknown what the long-term effect of USPIV placement will be on fistula creation in chronic kidney disease (CKD) patients considering these ultrasound-guided peripheral lines often target the same deeper vessels used for fistulas. This study aimed to survey whether emergency medicine programs place restrictions on USPIV placement in patients with CKD stages 3-5.
This was a survey study encompassing all 110 emergency ultrasound fellowship directors in the United States at the time the survey was conducted. Data was collected on an anonymous and voluntary basis. The primary outcome was the number of programs with restrictions on USPIV placement in patients with CKD stage 3 or greater.
Of the 56 programs that responded, 21% reported having policies limiting which patients were appropriate for USPIV. Despite this, only one program reported placing restrictions on USPIV in CKD stage 3 or greater ( < 0.0001).
Emergency departments do not have or follow restrictions placed on USPIV placement in patients with CKD stage 3 or greater. The use of these veins in the ED may result in thrombosis as well as inflammation and permanent scarring which could negatively impact the ability to utilize those vessels for fistula creation. Future studies are needed to further characterize the impact of USPIV on fistula creation.
在急诊科(ED)患者中,超声引导下外周静脉(USPIV)置管的应用频率越来越高。USPIV 置管已被证明可提高置管成功率。目前尚不清楚在考虑这些超声引导下外周静脉通常针对用于造瘘的相同深部血管时,USPIV 置管对慢性肾脏病(CKD)患者瘘管形成的长期影响如何。本研究旨在调查考虑到这些超声引导下外周静脉通常针对用于造瘘的相同深部血管时,CKD 3-5 期患者的紧急医学项目是否对 USPIV 置管有任何限制。
这是一项调查研究,涵盖了在进行调查时美国所有 110 个急诊超声研究员项目的主任。数据是在匿名和自愿的基础上收集的。主要结果是在 CKD 3 期或更严重的患者中,USPIV 置管受限的项目数量。
在 56 个做出回应的项目中,21%报告有政策限制哪些患者适合进行 USPIV。尽管如此,只有一个项目报告对 CKD 3 期或更严重的患者限制使用 USPIV( < 0.0001)。
急诊科没有或不遵循对 CKD 3 期或更严重的患者进行 USPIV 置管的限制。这些静脉在 ED 的使用可能导致血栓形成以及炎症和永久性瘢痕形成,这可能会对利用这些血管进行瘘管形成的能力产生负面影响。需要进一步研究以进一步确定 USPIV 对瘘管形成的影响。